AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BCAX

Cohlhepp Ryan sold $401K of BCAX

Cohlhepp Ryan (President, COO & Interim CEO) sold 17,500 shares of Bicara Therapeutics Inc. (BCAX) at an average of $22.90 ($22.77–$23.43, $0.40M total) across 2 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cohlhepp Ryan
Published Sep 10, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCAX
Neutral
medium confidence
Mentioned
$BCAX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCAXNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited actionable insight.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming dilution from future financing rounds

Relevance 3/10Novelty 4/10Timing: filed after market close on Sep 10

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

$BCAXNeutralMedium confidence
Context

President/COO sold ~ $401K of shares via 10b5-1 plan

Expected impact

Limited short-term impact; may cause slight downward pressure

Evidence & confidence

Sale amount is small relative to market cap and follows a pre‑arranged plan, reducing informational value

Market effects

Sector

None beyond the company

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider could be cashing out ahead of upcoming clinical data release

Key entities

  • Company
    Bicara Therapeutics Inc.

    Biotech firm developing therapies for rare diseases

  • Insider
    Cohlhepp Ryan

    President, COO & Interim CEO of Bicara Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCAX insider trading history →

Related articles

$BCAXMedAI 8/10

Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights: Strong Enrollment Momentum

Bicara Therapeutics (BCAX) reported Q3 2026 earnings, highlighting strong enrollment in FORTIFY-HN01 and FORTIFY-FLEX trials. Interim overall survival analysis is planned but timing is unclear. The company expects to report response data, with durability and depth underpinning overall survival predictions. Bicara aims for a competitive launch of ficerafusp alfa, targeting a differentiated BLA and premium pricing based on value.

finance.yahoo.com
$BCAXMedAI 8/10

What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call

Bicara Therapeutics (BCAX) reported Q3 earnings, highlighting FICERA's potential in HPV-negative head and neck cancer. Key data includes a 54% objective response rate and 21-month median overall survival. The company expects funding to last into 2029. Bicara is also studying FICERA in colorectal cancer and plans to present data in 2027.

finance.yahoo.com
$BCAXMed

Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 Enrolling FORTIFI-FLEX alternate do

SEC EDGAR 8-K
$BCAXMedAI 8/10

BofA reiterates Bicara Therapeutics stock rating on EGFR therapy potential

BofA Securities reiterated a Buy rating and $34.00 price target for Bicara Therapeutics (BCAX) after Genmab's positive trial results. BCAX shares fell 44% to $9.76, near a 52-week low. BofA noted the results validate next-gen EGFR therapies but do not change its view of Bicara's ficerafusp alfa. The firm highlighted BCAX's $161M enterprise value and strong cash position. Other analysts also gave positive ratings and price targets.

investing.com